[EN] CYCLIN-DEPENDENT KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASES CYCLINE-DÉPENDANTES
申请人:SPV THERAPEUTICS INC
公开号:WO2020140055A1
公开(公告)日:2020-07-02
Described herein are compounds and their pharmaceutically acceptable salts, pharmaceutical compositions thereof, methods of treatment, and medical uses. The compounds described herein are modulators of cyclin-dependent kinases, and are useful in the treatment or alleviation of protein kinase associated disorders, including cancer, infectious diseases, autoimmune diseases, or cardiovascular diseases.
[EN] CYCLIN-DEPENDENT KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASE CYCLINE-DÉPENDANTS
申请人:SPV THERAPEUTICS INC
公开号:WO2020140054A1
公开(公告)日:2020-07-02
Described herein are compounds and their pharmaceutically acceptable salts, pharmaceutical compositions thereof, methods of treatment, and medical uses. The compounds described herein are modulators of cyclin-dependent kinases, and are useful in the treatment or alleviation of protein kinase associated disorders, including cancer, infectious diseases, autoimmune diseases, or cardiovascular diseases.
New Synthetic Approach to Cyclopenta-Fused Heterocycles Based upon a Mild Nazarov Reaction
作者:Ernesto G. Occhiato、Cristina Prandi、Alessandro Ferrali、Antonio Guarna、Paolo Venturello
DOI:10.1021/jo034939p
日期:2003.12.1
role in forcing the conrotatory process to take place in one sense only: allowing the synthesis of diastereomerically pure compounds to be realized. Because different patterns of substitution on the heterocycle are compatible with the reaction conditions, the methodology developed could be very useful for the synthesis of natural products and biologically active compounds containing cyclopenta-fused O-